辅助化疗XELOX方案治疗结直肠癌患者的疗效及对免疫系统的影响

Efficacy of Adjuvant Chemotherapy XELOX Regimen in the Treatment of Colorectal Cancer Patients and Its Impact on the Immune System

目的探究辅助化疗XELOX方案治疗结直肠癌患者的疗效及对免疫系统的影响。方法选取2018年4月—2021年5月该院103例结直肠癌患者为研究对象。基于治疗差异分为两组,对照组51例,予FOLFOX方案;观察组52例,予以XELOX方案。对比评估两组不良反应、治疗效果及免疫系统功能。结果观察组口腔黏膜炎(3.85%)、中性粒细胞减少(11.54%)、腹泻(9.62%)、神经毒素(21.15%)、恶心呕吐(21.15%)低于对照组(27.45%、49.02%、45.10%、60.78%、49.02%),差异有统计学意义(χ^(2)=10.934、17.193、16.377、16.745、8.794,P<0.05);治疗后,CD8^(+)(25.63±2.55)%、CD4^(+)(34.39±2.43)%、CD3^(+)(52.91±4.35)%、NK(21.93±1.12)%高于对照组(20.34±2.41)、(31.23±2.31)、(47.13±4.07)、(18.38±1.08)%,差异有统计学意义(t=-10.816、-6.762、-6.960、-16.370,P<0.05)。结论结直肠癌辅助化疗应用XELOX方案效果理想。

Objective To explore the efficacy of adjuvant chemotherapy XELOX regimen in the treatment of colorectal cancer patients and its impact on the immune system.Methods From April 2018 to May 2021,103 patients with colorectal cancer in the hospital were selected as the research objects.Based on the difference in treatment,they were divided into two groups,51 patients in the control group was given FOLFOX regimen;52 patients in the observation group was given XELOX regimen.The adverse reactions,treatment effects and immune system function of the two groups were compared and evaluated.Results The rates of oral mucositis(3.85%),neutropenia(11.54%),diarrhea(9.62%),neurotoxin(21.15%),nausea and vomiting(21.15%)in the observation group were lower than those in the control group(27.45%,49.02%,45.10%,60.78%,49.02%),and the difference was statistically significant(χ^(2)=10.934,17.193,16.377,16.745,8.794,P<0.05).After treatment,the immune indexes of CD8^(+)(25.63±2.55)%,CD4^(+)(34.39±2.43)%,CD3^(+)(52.91±4.35)%,NK(21.93±1.12)%were higher than those of the control group(20.34±2.41)%,(31.23±2.31)%,(47.13±4.07)%,(18.38±1.08)%,and the difference was statistically significant(t=-10.816,-6.762,-6.960,-16.370,P<0.05).Conclusion Adjuvant chemotherapy for colorectal cancer using XELOX regimen has an ideal effect.